Otsuka agrees to acquire Transcend Therapeutics for $1.22bn
Under the agreement, Otsuka will pay $700m to Transcend shareholders upon closing.
Drug Development
Novo Nordisk receives FDA approval for basal insulin Awiqli
Novartis to acquire Excellergy for $2bn upfront
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Cognito Therapeutics and Ochsner partner for new brain health approaches
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
Researchers become scientific tastemakers by handing more R&D to autonomous labs
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
